Arena Pharmaceuticals Inc


  • After-Hours Buzz: AIG, LNKD, GILD & More Thursday, 2 May 2013 | 4:40 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • San Diego: The New Silicon Valley of Biotechnology? Thursday, 11 Apr 2013 | 1:07 PM ET
    San Diego

    San Diego is at ease with sandy beaches, and biotechnology.

  • Predictions for FDA Drug Approvals Tuesday, 12 Mar 2013 | 12:13 PM ET

    TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.

  • Lightning Round: DuPont, Phillips 66 & More Tuesday, 5 Feb 2013 | 6:36 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Big Pharma Bets on Obesity Drug Binge Thursday, 27 Dec 2012 | 2:18 AM ET

    As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • How to Profit From Alexza Pharma FDA Ruling Wednesday, 19 Dec 2012 | 12:29 PM ET

    Here's how to profit from the coming Alexza FDA run down.

  • Lightning Round: Gold, Hain and More Monday, 17 Dec 2012 | 7:19 PM ET

    Are you ready skeedaddy??! It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.

  • Orexigen plans public offering of its stock Wednesday, 24 Oct 2012 | 6:21 PM ET

    Credit Suisse Securities LLC, BofA Merrill Lynch and Leerink Swann LLC will act as joint managers. The company hopes to file in late 2013, triggering a 10- month review process by the FDA. The FDA refused to approve the drug in February 2011.

  • Vivus shares slip after analyst cautions on Qsymia Thursday, 18 Oct 2012 | 1:43 PM ET

    Shares of Vivus Inc. tumbled Thursday after an analyst said Wall Street may be over-estimating gains from initial sales of the drug developer's obesity treatment Qsymia. THE BIG PICTURE: Qsymia, Vivus' only approved drug, launched in the U.S. in September.

  • Big Pharma Dividend Plays  Monday, 1 Oct 2012 | 1:55 PM ET

    CNBC's Seema Mody anticipates which pharma stocks could raise their dividends in the months ahead.

  • Stocks to Watch: HRB, PAY, SVU & More Wednesday, 5 Sep 2012 | 4:51 PM ET

    Check out which companies are making headlines after the bell Wednesday.

  • Deutsche Bank’s 4 Large Bank Stock Picks Thursday, 26 Jul 2012 | 1:40 PM ET

    Large regional banks continue to outperform the money center banks, despite the compelling stock price multiples for the largest bank holding companies.

  • Stocks End Higher, Dow Up 100; BofA Falls 5% Wednesday, 18 Jul 2012 | 4:59 PM ET

    Stocks finished higher for a second session Wednesday, led by techs, after Bernanke reiterated that the central bank stands ready to inject more stimulus and despite the Fed's latest lackluster "Beige Book" report.

  • Futures Hold Losses After Housing Starts Wednesday, 18 Jul 2012 | 9:14 AM ET

    U.S. stock index futures held their losses Wednesday ahead of a second day of Congressional testimony from Federal Reserve chairman Ben Bernanke.

  • A Biotech Short-Seller Responds to Critics Tuesday, 17 Jul 2012 | 12:24 PM ET

    Short selling is never going to be a wildly popular investing practice, but it is perfectly legal and essential for the proper function of the capital markets. I asked a biotech short seller for his thoughts on why long investors seem so hostile to short sellers and whether this animosity will compel short sellers to be even more reluctant to voice their opinions publicly.

  • No Magic in Anti-Obesity Pills and Profits Monday, 16 Jul 2012 | 6:17 PM ET

    Jim Cramer’s researcher, Nicole Urken, reiterates the importance of assessing risk when speculating.

  • Jim Cramer

    Investors need to see this as a speculative stock and take some profits as they come in, he said.

  • Your All-Star in Cramer's #StockDerby Tuesday, 10 Jul 2012 | 6:46 PM ET

    Find out which second-quarter top performer got the most votes.